← Leaderboards
Dirk Pleimes
Biosputnik Llc
$378,537
Attributed
$857,413
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $601K · FY2021–23$1M$750K$500K$250K$0
'21
'22
'23
Funding mix
By agency
NIH$857,413 · 3
By mechanism
R41$857,413 · 3
Top collaborators
- Vera P Krymskaya3 shared
- Jacob Brenner1 shared
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoLung DiseasesGrantIn VitroLesionLungClinical DevelopmentGeneticInvestigationDisadvantagedFda ApprovedExperimental StudyLifeFemale Of Child Bearing AgeCell Culture TechniquesCategoriesFrap1 GeneCellsImmunosuppressive AgentsInheritedAntibodiesCystAffectLymphangioleiomyomatosis
Grant awards (3)
miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis$301,016
R41 · FY2023 · HG · contact PI
Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)$299,997
R41 · FY2023 · HL · contact PI
Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis$256,400
R41 · FY2021 · HL · contact PI